undamentalytics Newsletter
Sign in

Medicinova Inc income statement

In fiscal 2025, Medicinova Inc reported revenue of $409,657, down 59.0% on the year before, operating income of −$13.3m (a -3242.5% margin) and net income of −$12.0m, or −$0.24 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122021Dec 20212023Dec 20232025Dec 2025LTMJun 2026
Revenue14101
Research and development58575
General and administrative76567
Operating income−11−10−10−13−12
Income before tax−11−10−9−12—
Income tax0000—
Net income−11−10−9−12−11
Diluted EPS−$0.22−$0.21−$0.17−$0.24−$0.22
Diluted shares (average)50m49m49m49m49m
EBITDA−11−10−10−13−12

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MNOV vs STTKLGVN vs MNOVDARE vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Medicinova Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Medicinova Inc.